US 7,456,169 B2
Heterocyclic kinase inhibitors
Lisa A. Hasvold, Grayslake, Ill. (US); Laura Hexamer, Gurnee, Ill. (US); Gaoquan Li, Madison, Wis. (US); Nan-Horng Lin, Vernon Hills, Ill. (US); Hing Sham, South San Francisco, Calif. (US); Thomas J. Sowin, Wadsworth, Ill. (US); Gerard M. Sullivan, Labe Villa, Ill. (US); Le Wang, Mundelein, Ill. (US); and Ping Xia, St. Louis, Mo. (US)
Assigned to Abbott Laboratories Inc., Abbott Park, Ill. (US)
Filed on Aug. 23, 2006, as Appl. No. 11/466,638.
Application 11/466638 is a continuation in part of application No. 10/785120, filed on Feb. 25, 2004, abandoned.
Claims priority of provisional application 60/450476, filed on Feb. 27, 2003.
Prior Publication US 2007/0254867 A1, Nov. 01, 2007
Int. Cl. C07D 413/00 (2006.01); A61K 31/5513 (2006.01)
U.S. Cl. 514—220  [540/495] 2 Claims
 
2. The compound 2-[3-(3-methoxy-4-nitrophenyl)-11 -oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-N-(4-morpholin-4-ylphenyl)propanamide, or a therapeutically acceptable salt thereof.